Rigel Pharmaceuticals, Inc. (RIGL) Reports Q3 Loss of $0.25
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $45.89 +1.41%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q3 EPS of ($0.25), versus $0.96 reported last year. Revenue for the quarter came in at $4.35 million, versus $72.28 thousand reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- The Buckle (BKE) Tops Q2 EPS by 7c, Beats on Revenue
- Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
